Company: HROW
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021562
Chunk: 47

Company: HARROW, INC.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 47
---
and OPUVIZTM – Commercialization Agreement

In
July 2025, the Company entered into a development and commercialization agreement (the “Samsung Agreement”) with Samsung
Bioepis Co., Ltd. (“Samsung”). Under the terms of the Samsung Agreement, following completion of the transition of commercial
rights from Biogen, Inc. back to Samsung, Samsung will develop, manufacture, and supply BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy)
(individually, a “Product” and together, the “Products”) for Harrow to commercialize in the U.S. market (the
“Rights”). In consideration of such Rights, Harrow will make a one-time upfront payment to Samsung, and Samsung will be eligible
to receive additional one-time payments based on the achievement of net sales-based milestones of the Products. In addition to other
mutually agreed terms, Harrow shall pay to Samsung a share of net sales from the Products generated in the U.S. market.

    26

Acquisition
of Remaining Interests in Melt Pharmaceuticals, Inc. - Related Party

In
September 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company,
Harrow Acquisition Sub, Inc., a wholly owned subsidiary of the Company, Melt Pharmaceuticals, Inc. (“Melt”), and D. Brad
Osborne, as stockholder representative.

As
of September 30, 2025, the Company owned approximately 46% of Melt’s outstanding equity and also had a mid-single digit royalty
interest on future net sales of Melt’s primary product (MELT-300). Certain officers and directors of the Company, including Mark
L. Baum, the Company’s Chairman and Chief Executive Officer, and Andrew R. Boll, the Company’s President and Chief Financial
Officer, own additional equity interests in Melt, and Mr. Baum serves on the board of directors of Melt.

Under
the terms of the Merger Agreement and related milestone payment agreement, the Company agreed to acquire the remaining equity interests
of Melt in exchange for an initial cash payment of approximately $4,300,000 at closing, and contingent consideration consisting of cash
and Company equity upon achievement of (i) U.S. Food and Drug Administration (“FDA”) approval of the MELT-300 product candidate,
(ii) coding and reimbursement of